Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Inovio Pharmaceuticals to Present at Investor Conferences

April 29, 2011

BLUE BELL, Pa., April 29, 2011 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at three investor conferences:

JMP Securities Research Conference
San Francisco, CA, May 9-11, 2011
The Ritz-Carlton, San Francisco

Inovio Presentation
Dr. J. Joseph Kim, Ph.D., President & CEO
May 9, 2011
10:30 AM

http://www.jmpg.com/wp-content/files_mf/jmp_may2011_invite_v3.pdf

MDB Bright Lights Conference
New York, NY, May 10-11, 2011
Le Parker Meridien Hotel

Inovio Presentation
Thomas Kim, VP, IP and Associate General Counsel
May 11, 2011
10:00 AM

Bright Lights is an investment conference focused on publicly traded companies with disruptive and market changing intellectual property (IP). Inovio was selected from MDB’s 2011 group of “Best and Brightest” small-cap companies; a group that is advancing some of today’s most innovative and market-leading IP. Inovio is one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB’s proprietary IP business intelligence platform.

http://www.mdb.com/2011-bright-lights-conference.html

Noble Financial Investor Conference
Hollywood, FL, May 16-17, 2011
Hard Rock Hotel

Inovio Presentation
Dr. J. Joseph Kim, Ph.D., President & CEO
May 16, 2011
2:00 PM

http://www.nobleresearch.com/a/research/conference.php

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon(TM) vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio’s proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio’s clinical programs include three separate programs in Phase II clinical studies, including VGX-3100 for treating cervical dysplasia and cancer. Other Inovio clinical programs include those for avian flu (preventive) and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010 and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com

(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

SOURCE Inovio Pharmaceuticals, Inc.


Source: newswire